- In January 2024, the U.S. FDA granted approval for Casgevy, a CRISPR-based therapy, for its second indication: the treatment of transfusion-dependent beta thalassemia in patients aged 12 and older. This approval follows its previous authorization in December 2023 for the treatment of sickle cell disease. Casgevy's expanded approval marks a significant advancement in gene-editing therapies for blood disorders, offering new hope for patients with these conditions
- In August 2022, the U.S. FDA approved Zynteglo (beti-cel) as the first curative gene therapy for patients with beta thalassemia who require regular red blood cell transfusions. This approval represents a major breakthrough, offering the potential for long-term relief from transfusion dependence. Zynteglo uses gene editing to address the root cause of beta thalassemia, providing a transformative treatment option for patients
- In June 2021, the U.S. FDA granted breakthrough therapy designation to Rusfertide (PTG-300) as a potential treatment for polycythemia Vera. This designation recognizes its ability to reduce erythrocytosis in patients who do not require additional treatments for thrombocytosis or leucocytosis. The approval highlights Rusfertide's promising role in managing this rare blood disorder by targeting the underlying causes of excessive red blood cell production
- In April 2022, Himalaya Wellness Company partnered with the Sankalp India Foundation to provide support for thalassemia patients, focusing on offering a permanent curative option. This collaboration aims to facilitate bone marrow transplants, which can potentially cure the disease. By joining forces, the two organizations seek to improve access to life-changing treatments for thalassemia patients in need
Frequently Asked Questions
The market is segmented based on Segmentation, By Type (Alpha Thalassemia Silent Carrier, Alpha Thalassemia Carrier, Haemoglobin H Disease, Alpha Thalassemia Major, and Others), Diagnosis (Chorionic Villus Sampling, Amniocentesis, and Others), Treatment (Frequent Blood Transfusions, Chelation Therapy, Stem Cell Transplant, and Others), End-Users (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others) – Industry Trends and Forecast to 2032
.
The Global Alpha Thalassemia Market size was valued at USD 742.04 USD Million in 2024.
The Global Alpha Thalassemia Market is projected to grow at a CAGR of 6.12% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
